Testicular cancer is the most common solid tumor among young men aged 15 to 35 years. With advances in chemotherapies, even disseminated testicular cancer has high cure rates with combination chemotherapy. Systematic randomized trials have shown that cisplatin, etoposide, and bleomycin (PEB) combination chemotherapy remains the mainstay of treatment. However, such combination therapy itself bears the risk of complications, including secondary leukemia, therapy-related solid tumors, infertility, nephrotoxicity, neurotoxicity, and pulmonary and vascular toxicity (1) .
Several reports have been published about early and late vascular toxicities associated with chemotherapy, including acute myocardial infarction, cerebrovascular events, and Raynaud phenomenon. Cisplatin is thought to be the most likely agent causing myocardial infarction (1) . However, in a study conducted to evaluate the risk of acute vascular events in patients receiving cisplatin-based chemotherapy for testicular cancer, no evidence of an increased risk for subsequent showed the blood pressure was 110/70 mm Hg and the heart rate was 84 beats/min. The cardiac examination revealed normal first and second heart sounds, with no murmur. His lungs were clear to auscultation, and there was no hepatosplenomegaly. There were no significant pathologic findings in the rest of the physical examination.
In the electrocardiogram, the rhythm was sinus rhythm with ST segment elevation in the anterior derivations ( Fig. 1 ). He was immediately taken to the catheter laboratory for primary percutaneous transluminal coronary angioplasty (PTCA), with the resulting diagnosis of acute anterior myocardial infarction.
Left coronary angiography demonstrated normal left main coronary artery, with normal circumflex coronary artery. However, there was dense intracoronary thrombus in the proximal left anterior descending artery (LAD), starting from the septal branch ( Fig. 2 ). Right coronary angiography demonstrated a dominant and normal right coronary artery. Medical follow-up of the patient was planned.
The bedside echocardiographic examination showed hypokinesia in apical segments of the left ventricle. The global ejection fraction was 60%. There was apical thrombus with a diameter of 1.4 × 1.7 cm. The hematologic and biochemical laboratory data are summarized in Table 1 .
The patient's medical treatment was revised, and 100 mg aspirin, 5 mg enalapril, 150 mg metoprolol, 20 mg isosorbide dinitrate, 20 mg atorvastatin, 75 mg clopidogrel, and 2 × 0.6 mL enoxaparin were given as daily medical treatment. During hospitalization in the coronary care unit, he was totally asymptomatic, and chest pain did not recur. The patient was discharged asymptomatic with the same medical therapy, and he was still asymptomatic in the polyclinic control 1 month later.
DISCUSSION
Testicular cancer is the most common solid tumor among men aged 15 to 35 years. With advances in chemotherapies, even disseminated testicular cancer has high cure rates with combination chemotherapy. Systematic randomized trials have shown that cisplatin, etoposide, and bleomycin (PEB) combination chemotherapy remains the mainstay of treatment. However, such combination therapy itself bears the risk of complications, including secondary leukemia, therapy-related solid tumors, infertility, nephrotoxicity, neurotoxicity, and pulmonary and vascular toxicity. Cisplatin is well known to cause secondary nongerm cell malignancies, vascular toxicities, cerebrovascular events, peripheral neuropathy, nephrotoxicity, and azoospermia. Bleomycin is thought to be the most important drug in the pathogenesis of Raynaud phenomenon, and cisplatin is the most likely agent involved in myocardial infarction.
During the last 15 years, several case reports have been published about the development of myocardial infarction in especially young patients during chemotherapy for testicular cancer (3) (4) (5) . In some of these reports, myocardial infarction developed after just the first course of the therapy (4); however, in some cases, the infarctions occurred several months or years after chemotherapy (6) .
In a study where 48 patients with newly diagnosed testicular seminomas were monitored for a mean of 7 years after chemotherapy, 3 patients who also received prior chest radiation therapy died from acute myocardial infarction 2, 9, and 10 years after treatment and while free of disease (7) . In 1 interesting case, a 30-year-old man who underwent 4 courses of chemotherapy for a disseminated testicular seminoma presented with 3 arterial occlusive events and 1 silent myocardial infarction. The report noted that the events occurred approximately 10 days after the start of each chemotherapy course, and after completion of chemotherapy, the patient remained in complete remission and free of new thromboembolic events (8) .
Because most of the patients in these reports had no significant risk factors for coronary artery disease, the chemotherapy regimen was thought to cause infarction. Lesions of the endothelium with obstructive coronary fibrosis, disorders of the clotting system, and coronary vasospasm are the most probable mechanisms in the pathogenesis of the assumed coronary toxicity (6). Doll et al (9) reported that a patient with germ-cell tumors of the testis had myocardial infarction after treatment with cisplatin-based combination therapy, noting that the Raynaud phenomenon preceded acute myocardial infarction with angiographic evidence of ergonovine-induced coronary artery spasm (9) .
In our patient, myocardial infarction developed during the second course of chemotherapy. Because there was no other coronary risk factor and coronary angiographic examination revealed thrombus in the LAD rather than atherosclerotic plaque, a hypercoagulability state or endothelial damage induced by chemotherapy might have caused the intracoronary thrombus. A chemotherapy-induced hypercoagulability state might also be the reason of the apical thrombus in our patient.
Despite the reports about the risk of myocardial infarction, in a study conducted to evaluate the risk of acute vascular events in patients receiving cisplatin-based chemotherapy for testicular cancer, no evidence of an increased risk for subsequent cardiovascular disease was maintained in this patient population (2) . The same study suggested that chemotherapeutic agents might not be the only explanation for the myocardial infarctions because all of these patients had risk factors for a hypercoagulable state in that they all had active malignancy, recent surgery, and debility related to intensive treatment. Deep venous thrombosis and pulmonary embolism are actually well-recognized complications of cancer. A multicenter study reported that advanced malignancies, renal carcinoma, and pancreatic, gastric, and brain tumors were independent variables strongly associated with the occurrence of venous thrombosis (10) . Lin et al (11) noted that patients with malignant disease might be at increased risk for recurrent venous thromboembolic events after development of new metastases or multiple episodes of neutropenia, especially those patients with a history of venous thromboembolic events. Harrington et al (12) showed that the median interval from cancer diagnosis to the initial episode of cancer-related thromboembolic disease was 8 months (range, 0-112 months).
In most of the studies of solid tumors, deep venous thrombosis and pulmonary embolism were shown as the most common thrombotic complications rather than thrombosis in coronary arteries. In their study, Nichols et al (2) suggested that reports of cisplatin-based chemotherapy-induced thrombotic events represented either coincidence or disease-related factors. However, Berliner et al (13) reported 6 patients with no previous signs or symptoms suggestive of coronary artery disease developed acute myocardial infarction shortly after cisplatin-based chemotherapy. Like their report, we reported a patient with no known coronary risk factors who developed myocardial infarction after the same chemotherapy regimen. We suggest that the myocardial infarction was chemotherapy associated because the patient had no other known coronary risk factors and coronary angiographic examination revealed no atherosclerotic plaque but only thrombus in LAD. However, one should not omit the effect of the neoplasm and surgery on the formation of hypercoagulable state.
CONCLUSION
Given the potential cure rates in this young group of patients, the benefits far outweigh the risks, despite these complications. But special attention should be paid to patients who already have other coronary risk factors. Further studies should be performed to determine why some patients are more susceptible to develop myocardial infarction after standard chemotherapy regimens, to define higher risk groups, and to prevent such vascular complications.
